|
|||||
|
|
Consequences of patient access restrictions to branded oxycodone hydrochloride extended-release tablets on healthcare utilization and costs in US health plans |
|
| Authors: | Rami Ben-Joseph Chi-Chang Chen Ajita P. De Rolin L. Wade Dhvani Shah |
| Affiliation: | IMS Health, Plymouth Meeting, PA, USA Purdue Pharma L.P.Stamford, CTUSA |
| Abstract: | |
| Keywords: | Chronic pain ER/LA opioid Prior authorization Tier change Access restriction Cost Utilization |